Clinical Trials
13 trialsNCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02954874 2026-05-15
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02194738 2026-05-13
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT02595944 2026-05-13
ANVIL
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03233711 2026-05-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03244384 2026-05-13
AMBASSADOR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03811015 2026-05-13
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02193282 2026-05-04
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03055013 2026-05-04
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01169337 2026-05-01
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-05-01
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01251861 2026-04-29
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02275533 2026-04-13
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting